Zoll Medical Corporation (NasdaqGS: ZOLL), a manufacturer of
resuscitation devices and software solutions, today announced that
revenues for the first quarter of fiscal 2010 increased 18% to
$105,212,000, compared to revenues in the first quarter of last year of
$89,462,000. Revenue results included a positive foreign exchange impact
of approximately $2.3 million compared to the first quarter of fiscal
2009. The results include approximately $4.6 million of revenue derived
from our new Temperature Management business, whose assets were acquired
from Alsius Corporation in May 2009. Net income was $2,310,000 for the
quarter, compared to $2,894,000 in the prior year. Diluted earnings per
share were $0.11, compared to $0.14 in the prior year. Backlog at the
end of the first quarter was approximately $17.0 million, as compared to
$8.3 million at the end of Q1 2009.
First quarter sales to the North American market were $75.5 million, an
increase of 15% compared to $65.7 million for the prior-year period.
Sales to the North American hospital market, including $2.7 million
related to our newly acquired Temperature Management business, increased
22% to $24.8 million, compared to $20.3 million for the same period last
year. North American hospital revenues included US Military/Big
Government sales of $6.5 million in the first quarter of fiscal 2010
compared to $5.6 million for the same period in the prior year. Sales to
the North American pre-hospital market increased 14% to $44.6 million,
compared to $39.1 million in the prior year. International sales,
including $1.9 million related to Temperature Management, increased 25%
to $29.8 million, compared to $23.8 million last year. LifeVest®
revenues increased 73% to $14.9 million. Total AutoPulse® sales
decreased 13% to $3.9 million, compared to $4.5 million in the first
quarter of last year.
Gross margin for the first quarter was 53%, compared to 52% in the first
quarter of fiscal 2009. The increase reflected an increased mix of sales
from the LifeVest product and the positive impact from foreign exchange
on foreign sales, partially offset by inclusion of our early-stage
temperature management product sales.
Richard A. Packer, Chief Executive Officer of ZOLL, commented, "We are
pleased to have achieved such strong growth, even with some parts of our
business still awaiting a resumption of buying. Our revenue growth in Q1
was primarily driven by growth in the LifeVest, Temperature Management
and International businesses. However, the North American Hospital and
Pre-hospital businesses continue to face spending constraints within the
capital equipment market.”
Commenting further on the year, Mr. Packer stated, "While the North
American Hospital and EMS environments continue to be challenging,
revenues for those markets in total were consistent with the first
quarter of 2009. We did receive a modest benefit from sales of Welch
Allyn AED products in AED sales. The military business also had a good
quarter and was consistent with the prior year. As we outlined going
into this year, if the core business simply remains flat while we await
a spending rebound, we expect the growth businesses would be strong
enough to achieve this year’s plans. This is what occurred in Q1.”
Mr. Packer concluded, "Overall, North American Hospital sales were a
small step in the right direction, and the LifeVest and Temperature
Management are continuing to gain momentum, and perform impressively.
Moving through the year, we expect to increase our level of
profitability as we gain leverage in these high growth businesses. We
believe we are on track for the year and our outlook for 2010 is
unchanged.”
ZOLL will host a conference call on Thursday, January 28, 2010 at 10:30
a.m. EST to discuss its first quarter financial results. This conference
call will be accessible on the Company’s home page at www.zoll.com.
Recorded replays of this conference call will be available on the web
page beginning later that day.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and
software solutions that help advance emergency care and save lives,
while increasing clinical and operational efficiencies. With products
for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management,
ZOLL provides a comprehensive set of technologies which help clinicians,
EMS and fire professionals, and lay rescuers treat victims needing
resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company
for the past three years, ZOLL develops and manufactures its products in
the United States, in California, Colorado, Illinois, Massachusetts,
Pennsylvania, and Rhode Island. More than 400 direct sales and service
representatives, 1,100 business partners, and 200 independent
representatives serve our customers in over 140 countries around the
globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including
statements regarding the anticipated development of the Company's
business,
our belief regarding revenues,
and other
statements contained herein regarding matters that are not historical
facts, are "forward-looking” statements (as defined in the Private
Securities Litigation Reform Act of 1995).
Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements.
Factors that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, those
factors discussed in the section entitled "Risk Factors” in the
Company's Annual Report on Form 10-K filed with the SEC on December 10,
2009. You should not place undue reliance on the forward-looking
statements in this press release, and the Company disavows any
obligation to update or supplement those statements in the event of any
changes in the facts, circumstances, or expectations that underlie those
statements.
© 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road,
Chelmsford, MA 01824-4105. AutoPulse, LifeVest, and ZOLL are registered
trademarks of ZOLL Medical Corporation. All trademarks are property of
their respective owners.
|
ZOLL MEDICAL CORPORATION
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
September 27,
|
|
|
|
2010
|
|
2009
|
|
ASSETS
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
56,299
|
|
$
|
51,061
|
|
Short-term investments
|
|
|
7,524
|
|
|
7,583
|
|
Accounts receivable, net
|
|
|
76,583
|
|
|
80,535
|
|
Inventory
|
|
|
73,634
|
|
|
69,700
|
|
Prepaid expenses and other current assets
|
|
|
21,455
|
|
|
21,240
|
|
Total current assets
|
|
|
235,495
|
|
|
230,119
|
|
Property and equipment, net
|
|
|
45,208
|
|
|
40,640
|
|
Other assets, net
|
|
|
100,798
|
|
|
101,088
|
|
|
|
$
|
381,501
|
|
$
|
371,847
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
Current and other liabilities:
|
|
|
|
|
|
Accounts payable
|
|
$
|
24,676
|
|
$
|
20,036
|
|
Accrued expenses and other liabilities
|
|
|
68,097
|
|
|
71,253
|
|
Total liabilities
|
|
|
92,773
|
|
|
91,289
|
|
Total stockholders’ equity
|
|
|
288,728
|
|
|
280,558
|
|
|
|
$
|
381,501
|
|
$
|
371,847
|
|
ZOLL MEDICAL CORPORATION
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
(In thousands, except per share data)
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
January 3,
|
|
December 28,
|
|
|
|
2010
|
|
2008
|
|
Net sales
|
|
$
|
105,212
|
|
$
|
89,462
|
|
Cost of goods sold
|
|
|
49,041
|
|
|
42,549
|
|
Gross profit
|
|
|
56,171
|
|
|
46,913
|
|
Expenses:
|
|
|
|
|
|
Selling and marketing
|
|
|
31,611
|
|
|
26,549
|
|
General and administrative
|
|
|
9,511
|
|
|
7,633
|
|
Research and development
|
|
|
11,363
|
|
|
7,969
|
|
Total expenses
|
|
|
52,485
|
|
|
42,151
|
|
Income from operations
|
|
|
3,686
|
|
|
4,762
|
|
Other expense, net
|
|
|
22
|
|
|
869
|
|
Income before taxes
|
|
|
3,664
|
|
|
3,893
|
|
Taxes
|
|
|
1,354
|
|
|
999
|
|
Net income
|
|
$
|
2,310
|
|
$
|
2,894
|
|
Earnings per share:
|
|
|
|
|
|
Basic
|
|
$
|
0.11
|
|
$
|
0.14
|
|
Diluted
|
|
$
|
0.11
|
|
$
|
0.14
|
|
Weighted average common shares:
|
|
|
|
|
|
Basic
|
|
|
21,215
|
|
|
21,061
|
|
Diluted
|
|
|
21,503
|
|
|
21,304
|